Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ETH-155008

Phase 1Small molecule

SShengke Pharmaceuticals Pty Ltd

ETH-155008 is one of 23 small molecule programs targeting AML. It is currently in Phase 1.

1

Indications

2

Total Trials

1

Active Trials

22

Competitors

Pipeline

Status by Indication[3][1]

Indication

AMLRecruiting

AMLPhase 1

Recruiting

Competition

Competitive Landscape

28 competitors in AML

#DrugCompanyPhaseTrials

Fludara

Cytosar

Venclexta

Idamycin

Cerubidine

HHikma Pharmaceuticals LLC

Cytoxan

BBaxter Healthcare Corporation

Homoharringtonine

Ascentage Pharma Group Inc.

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Tibsovo

Xospata

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

AML1 trial

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

Recruiting·SShengke Pharmaceuticals (Jiangsu) Limited, China·Phase 1·NCT05758610·60 enrolled

CLL/SLL1 trial

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Terminated·SShengke Pharmaceuticals Pty Ltd·Phase 1·NCT04840784·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ETH-155008. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ETH-155008 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ETH-155008. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shengke Pharmaceuticals Pty Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShengke Pharmaceuticals Pty Ltd

Related News